Genetic predisposition to leukemia and other hematologic malignancies

Seminars in Oncology

Volumn 43, Issue 5, 2016, Pages 598-608

  Feurstein, Simone ^a,b   Drazer, Michael W ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Familial leukemia; Genetic risk

Indexed keywords

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW DEPRESSION; FAMILIAL CANCER; GENETIC PREDISPOSITION; GENETIC RISK; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; REVIEW; WALDENSTROEM MACROGLOBULINEMIA; GENETICS; MYELODYSPLASTIC SYNDROMES;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA; LYMPHOMA; MYELODYSPLASTIC SYNDROMES;

EID: 84999266606     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.10.003     Document Type: Review

References (92)

1. [1] Churpek, J.E., Nickels, E., Marquez, R., et al. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood 120 (2012), 5247–5249.
2. [2] Song, W.J., Sullivan, M.G., Legare, R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23 (1999), 166–175.
3. [3] Smith, M.L., Cavenagh, J.D., Lister, T.A., Fitzgibbon, J., Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351 (2004), 2403–2407.
4. [4] Kirwan, M., Walne, A.J., Plagnol, V., et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet 90 (2012), 888–892.
5. [5] Polprasert, C., Schulze, I., Sekeres, M.A., et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27 (2015), 658–670.
6. [6] The University of Chicago Hematopoietic Malignancies Cancer Risk Team, How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 128 (2016), 1800–1813.
7. [7] Pippucci, T., Savoia, A., Perrotta, S., et al. Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 88 (2011), 115–120 [PubMed: 21211618].
8. [8] Vinh, D.C., Patel, S.Y., Uzel, G., et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115 (2010), 1519–1529.
9. [9] Toya, T., Yoshimi, A., Morioka, T., et al. Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia. Platelets 25 (2014), 300–302.
10. [10] Godley, L.A., Inherited predisposition to acute myeloid leukemia. Semin Hematol 51 (2014), 306–321.
11. [11] Al Daama, S.A., Housawi, Y.H., Dridi, W., et al. A missense mutation in ANKRD26 segregates with thrombocytopenia. Blood 122 (2013), 461–462.
12. [12] Noris, P., Perrotta, S., Seri, M., et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 117 (2011), 6673–6680.
13. [13] Zhang, M.Y., Churpek, J.E., Keel, S.B., et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 47 (2015), 180–185.
14. [14] Topka, S., Vijai, J., Walsh, M.F., et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLOS Genet, 11, 2015, e1005262.
15. [15] Noetzli, L., Lo, R.W., Lee-Sherick, A.B., et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 47 (2015), 535–538.
16. [16] Wang, M., Gu, D., Du, M., et al. Common genetic variation in ETV6 is associated with colorectal cancer susceptibility. Nat Commun, 7, 2016, 11478.
17. [17] Pabst, T., Eyholzer, M., Haefliger, S., Schardt, J., Mueller, B.U., Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26 (2008), 5088–5093.
18. [18] Taskesen, E., Bullinger, L., Corbacioglu, A., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117 (2011), 2469–2475.
19. [19] Pastore, F., Kling, D., Hoster, E., et al. Long-term follow-up of cytogenetically normal CEBPA-mutated AML. J Hematol Oncol, 7, 2014, 55.
20. [20] Tawana, K., Wang, J., Renneville, A., et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126 (2015), 1214–1223.
21. [21] Lewinsohn, M., Brown, A.L., Weinel, L.M., et al. Novel germline DDX41 mutations define families with a lower age of MDS/AML onset, and lymphoid malignancies. Blood 127 (2016), 1017–1023.
22. [22] Collin, M., Dickinson, R., Bigley, V., Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol 169 (2015), 173–187.
23. [23] Churpek, J.E., Pyrtel, K., Kanchi, K.-L., et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126 (2015), 2484–2490.
24. [24] Micol, J.-B., Abdel-Wahab, O., Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica 99 (2014), 201–203.
25. [25] West, A.H., Godley, L.A., Churpek, J.E., Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 1310 (2014), 111–118.
26. [26] Stanley, S.E., Chen, J.J.L., Podlevsky, J.D., et al. Telomerase mutations in smokers with severe emphysema. J Clin Invest 125 (2015), 563–570.
27. [27] Parry, E.M., Alder, J.K., Qi, X., Chen, J.J.-L., Armanios, M., Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 117 (2011), 5607–5611.
28. [28] Sorrell, A.D., Espenschied, C.R., Culver, J.O., Weitzel, J.N., Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome. Mol Diagn Ther 17 (2013), 31–47.
29. [29] Churpek, J.E., Marquez, R., Neistadt, B., et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122 (2015), 304–311.
30. [30] Powell, B.C., Jiang, L., Muzny, D.M., et al. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 60 (2013), E1–E3.
31. [31] Riccardi, V.M., Trisomy 8: an international study of 70 patients. Birth Defects Orig Art Ser 13 (1977), 171–184.
32. [32] Davidsson, J., Veerla, S., Johansson, B., Constitutional trisomy 8 mosaicism as a model for epigenetic studies of aneuploidy. Epigenetics Chromatin, 6, 2013, 18.
33. [33] Shimamura, A., Alter, B.P., Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 24 (2010), 101–122.
34. [34] Alter, B.P., Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol 27 (2014), 214–221.
35. [35] Domchek, S.M., Tang, J., Stopfer, J., et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 3 (2013), 399–405.
36. [36] Vasanthakumar, A., Arnovitz, S., Marquez, R., et al. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood 127 (2016), 310–313.
37. [37] Sawyer, S.L., Tian, L., Kahkonen, M., et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 5 (2015), 135–142.
38. [38] Wilson, D.B., Link, D.C., Mason, P.J., Bessler, M., Inherited bone marrow failure syndromes in adolescents and young adults. Ann Med 46 (2014), 353–363.
39. [39] Kirwan, M., Dokal, I., Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 73 (2007), 103–112.
40. [40] Dhanraj, S., Gunja, S.M.R., Deveau, A.P., et al. Bone marrow failure and developmental delay caused by mutations in poly(A)-specific ribonuclease (PARN). J Med Genet 52 (2015), 738–748.
41. [41] Guo, Y., Kartawinata, M., Li, J., et al. Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1. Blood 124 (2014), 2767–2774.
42. [42] Alter, B.P., Giri, N., Savage, S.A., Rosenberg, P.S., Cancer in dyskeratosis congenita. Blood 113 (2009), 6549–6557.
43. [43] Savage, S.A., Bertuch, A.A., The genetics and clinical manifestations of telomere biology disorders. Genet Med 12 (2010), 753–764.
44. [44] Alsultan, A., Shamseldin, H.E., Osman, M.E., Aljabri, M., Alkuraya, F.S., MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts. Blood 122 (2013), 3844–3845.
45. [45] Bahrami E, Racek T, Witzel M, et al. A human bone marrow failure syndrome caused by a homozygous mutation in MYSM1. Paper presented at the 57th Annual Meeting of the American Society of Hematology; 2015 December 05; Orlando, FL.
46. [46] Nijnik, A., Clare, S., Hale, C., et al. The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiation. Blood 119 (2012), 1370–1379.
47. [47] Bruzzoni-Giovanelli, H., González, J.R., Sigaux, F., et al. Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. Oncotarget 6 (2015), 36269–36277.
48. [48] Jones, A.V., Cross, N.C.P., Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol 4 (2013), 237–253.
49. [49] Rumi, E., Passamonti, F., Della Porta, M.G., et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 25 (2007), 5630–5635.
50. [50] Skoda, R.C., Hereditary myeloproliferative disorders. Haematologica 95 (2010), 6–8.
51. [51] Saliba, J., Saint-Martin, C., Di Stefano, A., et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet 47 (2015), 1131–1140.
52. [52] Harutyunyan, A.S., Giambruno, R., Krendl, C., et al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood 127 (2016), 362–365.
53. [53] Kilpivaara, O., Mukherjee, S., Schram, A.M., et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nat Genet 41 (2009), 455–459.
54. [54] Jäger, R., Harutyunyan, A.S., Rumi, E., et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol 89 (2014), 1107–1110.
55. [55] Oddsson, A., Kristinsson, S.Y., Helgason, H., et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia 28 (2014), 1371–1374.
56. [56] Auer, F., Rüschendorf, F., Gombert, M., et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia 28 (2014), 1136–1138.
57. [57] Shah, S., Schrader, K.A., Waanders, E., et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45 (2013), 1226–1231.
58. [58] Perez-Garcia, A., Ambesi-Impiombato, A., Hadler, M., et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 122 (2013), 2425–2432.
59. [59] Spolverini, A., Pieri, L., Guglielmelli, P., et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative ׳idiopathic׳ erythrocytosis. Haematologica 98 (2013), e101–e102.
60. [60] Lesteven, E., Picque, M., Conejero Tonetti, C., et al. Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood 123 (2014), 794–796.
61. [61] Waxman, A.J., Mink, P.J., Devesa, S.S., et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116 (2010), 5501–5506.
62. [62] Kristinsson, S.Y., Björkholm, M., Goldin, L.R., et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125 (2009), 2147–2150.
63. [63] Broderick, P., Chubb, D., Johnson, D.C., et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 44 (2011), 58–61.
64. [64] Martino, A., Campa, D., Jamroziak, K., et al. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. Br J Haematol 158 (2012), 805–809.
65. [65] Weinhold, N., Johnson, D.C., Rawstron, A.C., et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 123 (2014), 2513–2517.
66. [66] Grass, S., Preuss, K.-D., Ahlgrimm, M., et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol 10 (2009), 950–956.
67. [67] Grass, S., Preuss, K.-D., Thome, S., et al. Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood 118 (2011), 635–637.
68. [68] Preuss, K.-D., Fadle, N., Regitz, E., Held, G., Pfreundschuh, M., Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits. Int J Cancer 135 (2014), 2046–2053.
69. [69] Roccaro, A.M., Sacco, A., Shi, J., et al. Exome sequencing reveals recurrent germline variants in patients with familial Waldenstrom macroglobulinemia. Blood 127 (2016), 2598–2606.
70. [70] Cerhan, J.R., Slager, S.L., Familial predisposition and genetic risk factors for lymphoma. Blood 126 (2015), 2265–2273.
71. [71] Morton, L.M., Purdue, M.P., Zheng, T., et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 18 (2009), 1259–1270.
72. [72] Hamadou, W.S., Abed, R.E., Besbes, S., et al. Familial hematological malignancies: ASXL1 gene investigation. Clin Transl Oncol. 18 (2016), 385–390.
73. [73] Bjorkholm, M., Sjoberg, J., Nygell, U.A., Porwit, A., Bjorck, E., Development of Hodgkin lymphoma in homozygotic triplets with constitutional deletion in MKL1. Blood, 121, 2013, 4807.
74. [74] Tran, H., Nourse, J., Hall, S., Green, M., Griffiths, L., Gandhi, M.K., Immunodeficiency-associated lymphomas. Blood Rev 22 (2008), 261–281.
75. [75] Nocturne, G., Boudaoud, S., Miceli-Richard, C., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 122 (2013), 4068–4076.
76. [76] Zhang, M.Y., Keel, S.B., Walsh, T., et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica 100 (2015), 42–48.
77. [77] Geyh, S., Öz, S., Cadeddu, R.-P., et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27 (2013), 1841–1851.
78. [78] Chandran, P., Le, Y., Li, Y., et al. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk Res 39 (2015), 486–493.
79. [79] Raaijmakers, M.H.G.P., Mukherjee, S., Guo, S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464 (2010), 852–857.
80. [80] Blau, O., Baldus, C.D., Hofmann, W.-K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118 (2011), 5583–5592.
81. [81] Huang, J.C., Basu, S.K., Zhao, X., et al. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood. Cancer J, 5, 2015, e302.
82. [82] Blau, O., Hofmann, W.-K., Baldus, C.D., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 35 (2007), 221–229.
83. [83] Lopez-Villar, O., Garcia, J.L., Sanchez-Guijo, F.M., et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome. Leukemia 23 (2009), 664–672.
84. [84] Ding, L., Ley, T.J., Larson, D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481 (2012), 506–510.
85. [85] Steensma, D.P., Bejar, R., Jaiswal, S., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.
86. [86] Kwok, B., Hall, J.M., Witte, J.S., et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126 (2015), 2355–2361.
87. [87] Wang, L., Swierczek, S.I., Drummond, J., et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28 (2014), 935–938.
88. [88] Peffault de Latour, R., Peters, C., et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transplant 50 (2015), 1168–1172.
89. [89] Khincha, P.P., Wentzensen, I.M., Giri, N., Alter, B.P., Savage, S.A., Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol 165 (2014), 349–357.
90. [90] Noris, P., Favier, R., Alessi, M.C., et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood 122 (2013), 1987–1989.
91. [91] Spinner, M.A., Sanchez, L.A., Hsu, A.P., et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123 (2014), 809–821.
92. [92] Gonzalez, K.D., Noltner, K.A., Buzin, C.H., et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 (2009), 1250–1256.